Laidlaw restated their buy rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a research report sent to investors on Tuesday. The firm currently has a $38.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $35.00.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets reissued a buy rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Needham & Company LLC reissued a buy rating and issued a $36.00 price objective (up from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Janney Montgomery Scott reissued a buy rating and issued a $35.00 price objective (up from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. Royal Bank Of Canada reissued a buy rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a research report on Friday, July 7th. Finally, Cantor Fitzgerald set a $40.00 price objective on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Monday, June 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $88.50.

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded down 0.570% during mid-day trading on Tuesday, reaching $27.015. 1,078,352 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $24.99 and a 200 day moving average price of $22.63. The firm’s market capitalization is $861.91 million. Flexion Therapeutics has a 12-month low of $15.93 and a 12-month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Analysts anticipate that Flexion Therapeutics will post ($3.75) EPS for the current fiscal year.

WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/11/flexion-therapeutics-inc-flxn-receives-buy-rating-from-laidlaw.html.

In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of the stock in a transaction dated Friday, September 1st. The stock was purchased at an average price of $24.15 per share, with a total value of $72,450.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $120,750. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 5,375 shares of company stock valued at $131,575 in the last ninety days. Corporate insiders own 15.98% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in FLXN. Bank of New York Mellon Corp lifted its position in shares of Flexion Therapeutics by 27.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after purchasing an additional 591,981 shares during the period. State Street Corp lifted its position in shares of Flexion Therapeutics by 66.3% in the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock worth $27,888,000 after purchasing an additional 549,948 shares during the period. Wasatch Advisors Inc. lifted its position in shares of Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after purchasing an additional 376,745 shares during the period. Nexthera Capital LP purchased a new stake in shares of Flexion Therapeutics in the 2nd quarter worth approximately $4,661,000. Finally, Pictet Asset Management Ltd. lifted its position in shares of Flexion Therapeutics by 73.7% in the 2nd quarter. Pictet Asset Management Ltd. now owns 472,796 shares of the specialty pharmaceutical company’s stock worth $8,080,000 after purchasing an additional 200,657 shares during the period. 83.26% of the stock is owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.